Vilon

Overview

Vilon is a synthetic dipeptide (Lys-Glu / KE) from the Khavinson bioregulator series, originally derived from thymus extracts and studied in Russian preclinical models as an immunomodulator and geroprotector. Not FDA-approved; all published evidence originates from a single research group.

Mechanism of Action

Proposed mechanism per the Khavinson model: KE penetrates cells and nuclei and modulates expression of immune- and senescence-related genes. Downstream pathways remain hypothetical; no validated receptor target has been identified.

Research Summary

Evidence is limited to Khavinson-group preclinical work. Khavinson & Anisimov (Dokl Biol Sci, 2000; PMID 10944717) reported that Vilon (L-Lys-L-Glu) inhibited spontaneous tumor growth and extended lifespan in CBA mice. A small Russian report on Vilon as an adjuvant in elderly colorectal-cancer patients (Kuznik et al., 2005; PMID 16075684) is non-randomized and unreplicated. No Western-framework clinical trials, pharmacokinetic, or dose-response studies have been published.

Vendors selling Vilon

Scored vendors carrying Vilon, ranked by trust grade. Grades are computed from indexed Certificates of Analysis. Full $/mg pricing is on the comparison page.

Reported Side Effects

• Injection site irritation

Compare Vilon with Others

Research References

• A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors and increases life span of mice (Khavinson & Anisimov) (2000)
• Application of peptide bioregulator Vilon in complex treatment of elderly cancer patients (2005)

Frequently asked questions

Has Vilon been independently lab-tested?

Disclosed Labs has collected 11 Certificates of Analysis (COA) for Vilon from 6 independent testing labs. 8 vendors have submitted material for testing. Products average 99.7% tested purity across the corpus. Full testing data is available at https://www.disclosedlabs.com/peptides/vilon/testing.

What is the average purity of Vilon on the market?

Based on 11 COAs analyzed by Disclosed Labs, Vilon products average 99.7% (±0.2%) tested purity. Individual vendor results vary; see per-vendor COA data at https://www.disclosedlabs.com/peptides/vilon/coas.

Where can researchers source Vilon?

5 vendors with Disclosed Labs trust grades currently list Vilon, including Peptidology, Peptide Supply Co., Verified Peptides. Compare live prices and lab-verified COAs at https://www.disclosedlabs.com/prices/vilon.

How does Vilon work?

Proposed mechanism per the Khavinson model: KE penetrates cells and nuclei and modulates expression of immune- and senescence-related genes. Downstream pathways remain hypothetical; no validated receptor target has been identified.

What does the research say about Vilon?

Evidence is limited to Khavinson-group preclinical work. Khavinson & Anisimov (Dokl Biol Sci, 2000; PMID 10944717) reported that Vilon (L-Lys-L-Glu) inhibited spontaneous tumor growth and extended lifespan in CBA mice. A small Russian report on Vilon as an adjuvant in elderly colorectal-cancer patients (Kuznik et al., 2005; PMID 16075684) is non-randomized and unreplicated. No Western-framework clinical trials, pharmacokinetic, or dose-response studies have been published.